Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer

A population PK-PD modeling and simulation results demonstrated a strong exposure-response relationship for ALC across dosing intervals, underscoring the mechanism-based therapeutic potential of rhIL-7-hyFc in cancer immunotherapy.

Authors

Kwan Cheol Pak
Donghoon Choi (ORCID: https://orcid.org/0000-0002-2009-9760)
Hyeong‐Seok Lim (ORCID: https://orcid.org/0000-0003-1420-8200)
Sang Min Lee (ORCID: https://orcid.org/0000-0002-2173-2193)
S H Park (ORCID: https://orcid.org/0009-0001-8224-1072)

Institutions

Asan Medical Center (KR)
University of Ulsan (KR)
OncoImmune (United States) (US)
Genexine (South Korea) (KR)

Publication Details

Journal: Drug Design Development and Therapy
Published: 2025-10-01
DOI: https://doi.org/10.2147/dddt.s564085
Primary Topic: Monoclonal and Polyclonal Antibodies Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer

Kwan Cheol Pak, Donghoon Choi, Hyeong‐Seok Lim, Sang Min Lee et al.

Oct 1, 2025

Drug Design Development and Therapy

Monoclonal and Polyclonal Antibodies Research

article

Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer

Kwan Cheol Pak, Donghoon Choi, Hyeong‐Seok Lim, Sang Min Lee, S H Park

October 1, 2025article en

Abstract

A population PK-PD modeling and simulation results demonstrated a strong exposure-response relationship for ALC across dosing intervals, underscoring the mechanism-based therapeutic potential of rhIL-7-hyFc in cancer immunotherapy.

Drug Design Development and TherapyVol. Volume 19

Asan Medical Center (KR), University of Ulsan (KR), OncoImmune (United States) (US), Genexine (South Korea) (KR)

Openalex Percentile: Top 55%

Monoclonal and Polyclonal Antibodies Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer — Kwan Cheol Pak, Donghoon Choi, et al. · Drug Design Development and Therapy (2025) | TGRS Research Map | TGRS